{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+to+the+Lung", "query": { "condition": "Metastatic Cancer to the Lung" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 337, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+to+the+Lung&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T20:00:18.492Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06472076", "title": "A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer, Non-Small Cell" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Belrestotug", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2024-06-10", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 8, "location_summary": "Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more", "locations": [ { "city": "Ocala", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06472076" }, { "nct_id": "NCT06236438", "title": "Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2024-04-10", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 19, "location_summary": "La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06236438" }, { "nct_id": "NCT07636785", "title": "A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma (HCC)", "Metastatic Uveal Melanoma", "Renal Cell Carcinoma (RCC)", "Nonsmall Cell Lung Cancer", "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "VMD-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VM Discovery, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 111, "start_date": "2026-07-16", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07636785" }, { "nct_id": "NCT00096265", "title": "Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Recurrent Non-Small Cell Lung Carcinoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2004-10-06", "completion_date": "2012-04-01", "has_results": true, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 80, "location_summary": "Scottsdale, Arizona • Burbank, California • Los Angeles, California + 67 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096265" }, { "nct_id": "NCT01594398", "title": "Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Non Small Cell Lung Cancer (NSCLC)", "Breast Cancer", "Estrogen Receptor Breast Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 14, "start_date": "2012-05", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2021-11-19", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 3, "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594398" }, { "nct_id": "NCT02132598", "title": "Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer (NSCLC)", "Metastases to the Brain" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Liza Villaruz, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-12", "completion_date": "2019-08-09", "has_results": true, "last_update_posted_date": "2021-03-10", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02132598" }, { "nct_id": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Carcinoma", "Adenoid Cystic Carcinoma", "Lung Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer", "Mesothelioma", "Esophageal Cancer", "Any Solid Tumors Progressed After a Prior Immunotherapy", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma HNSCC", "Salivary Gland Carcinomas", "Head and Neck Cancers - Salivary Gland", "Head and Neck Cancers - Nasopharyngeal", "Head and Neck Cancers - Throat", "Small Cell Lung Cancer ( SCLC )", "Lung Cancer (Locally Advanced or Metastatic)", "Head and Neck Cancers - Tonsils", "Head and Neck Cancers Hypopharynx", "Head and Neck Cancers Larynx", "Head and Neck Cancers Lip", "Head and Neck Cancers Nasopharynx", "Head and Neck Cancers Oral Cavity", "Head and Neck Cancers", "Head and Neck Cancers Oropharynx", "Head and Neck Cancers Trachea" ], "interventions": [ { "name": "VMD-928 100 mg Tablet", "type": "DRUG" }, { "name": "VMD-928 Tablet and Pembrolizumab (200 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VM Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 242, "start_date": "2018-06-08", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 14, "location_summary": "Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556228" }, { "nct_id": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive", "Adenocarcinoma", "Bile Duct Cancer", "Biliary Tract Cancer", "Bladder Cancer", "Breast Cancer", "Breast Neoplasm", "Carcinoma, Ductal", "Carcinoma, Hepatocellular", "Cancer", "Lung Cancer, Non-Small-Cell", "Carcinoma, Ovarian Epithelial", "Carcinoma, Small Cell", "Carcinoma, Squamous", "Carcinoma, Transitional Cell", "Colorectal Cancer", "Esophagogastric Junction Neoplasms", "Inflammatory Breast Cancer", "Stomach Neoplasms", "Malignant Neoplasms", "Ovarian Neoplasms", "Pancreatic Cancer", "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER-2 Protein Overexpression", "HER-2 Gene Amplification", "Prostate Cancer", "Head and Neck Cancer", "Endometrial Cancer", "Lung Cancer, Small Cell" ], "interventions": [ { "name": "CT-0508", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Carisma Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-02-02", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 7, "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660929" }, { "nct_id": "NCT02279433", "title": "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "DS6051b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2014-09", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Orange, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02279433" }, { "nct_id": "NCT03098550", "title": "A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2017-06-15", "completion_date": "2020-07-06", "has_results": true, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-09-28T20:00:18.492Z", "location_count": 5, "location_summary": "Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03098550" } ] }